VIROLOGICAL STUDIES OF RECIPIENTS OF HIV-1 VACCINES

HIV-1 疫苗接种者的病毒学研究

• 批准号: 3804792
• 负责人: J F MANISCHEWITZ
• 金额: --
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3804792
• 关键词: AIDS vaccines; CD4 molecule; HIV infections; Herpesviridae disease; antiviral agents; antiviral antibody; blood chemistry; clinical trials; cytomegalovirus; helper T lymphocyte; human immunodeficiency virus 1; human subject; human therapy evaluation; human tissue; immunization; saliva; serology /serodiagnosis; tissue /cell culture; urinalysis

Phase I trial of HIV-1 subunit vaccine (gp 160, Microgenesys), is under way at the NIAID. The laboratory of DNA Virus Research is following these vaccinees in terms of CMV isolation from different body fluids (saliva, blood, urine). Cultures of CMV are performed before and following vaccinations at regular time intervals. A second trial of this vaccine enrolled HIV-1 positive asymptomatic patients. It is hoped that stabilization of CD4 cell numbers in these patients will result in reduced incidence of sytemic CMV. A third trial has recently begun, using the Microgenesys subunit p24 vaccine to immunize HIV-1 seropositive asymptomatic patients.

HIV-1亚单位疫苗（gp 160，Microgenesys）的I期试验正在进行中， 在NIAID的方式。 DNA病毒研究实验室正在跟踪这些 从不同体液（唾液， 血液、尿液）。 CMV的培养在接种前和接种后进行 定期接种疫苗。 该疫苗的第二次试验招募了HIV-1阳性无症状 患者 希望这些患者中CD 4细胞数量的稳定 患者将导致系统性CMV的发生率降低。 第三审判 最近开始使用Microgenesys亚单位p24疫苗， 免疫HIV-1血清阳性无症状患者。